Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin

被引：140

作者：

Skiest, DJ ^{[1
]}

机构：

[1] Univ Texas, SW Med Ctr, Div Infect Dis, Dallas, TX 75390 USA

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2006年 / 44卷 / 02期

关键词：

D O I：

10.1128/JCM.44.2.655-656.2006

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Daptomycin, a new cyclic lipopeptide, was recently approved for the treatment of infections by gram-positive organisms, including infections with methicillin-resistant Staphylococcus aureus (MRSA). A patient infected with infected with MRSA developed resistance to daptomycin after prolonged exposure, which resulted in clinical failure. Clinicians should be aware of the possibility of daptomycin resistance and should consider routine testing for daptomycin susceptibility.

引用

页码：655 / 656

页数：2

共 5 条

[1] Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia [J].

Mangili, A ;

Bica, I ;

Snydman, DR ;

Hamera, DH .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (07) :1058-1060

[2] The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species [J].

Richter, SS ;

Kealey, DE ;

Murray, CT ;

Heilmann, KP ;

Coffman, SL ;

Doern, GV .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (01) :123-127

[3] In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains [J].

Rybak, MJ ;

Hershberger, E ;

Moldovan, T ;

Grucz, RG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1062-1066

[4] Resistance studies with daptomycin [J].

Silverman, JA ;

Oliver, N ;

Andrew, T ;

Li, T .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1799-1802

[5] Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections [J].

Steenbergen, JN ;

Alder, J ;

Thorne, GM ;

Tally, FP .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (03) :283-288

← 1 →